Search
for
Did you mean Janus Kinase Inhibitors?
Sort by
Research 30 of 1000+
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- A review of Janus kinase inhibitor use in scarring alopecia
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Inhibiting Janus kinases to treat alopecia areata
- Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
- 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review
- Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report
- The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B